<DOC>
	<DOCNO>NCT01030315</DOCNO>
	<brief_summary>Study design : - Phase I , first-in-human , randomize , double-blind , placebo-controlled , sequential dose escalation study intravenously administer HM10760A healthy adult Caucasian Japanese subject . Up 5 dose level cohort plan . In dose level cohort , subject randomize receive single dose HM10760A placebo . Primary Objective : - To evaluate safety profile single intravenous ( IV ) dose level HM10760A healthy adult Caucasian Japanese subject .</brief_summary>
	<brief_title>A Study HM10760A ( Long-acting Erythropoietin ) Healthy Adult Caucasian Japanese Subjects</brief_title>
	<detailed_description>Secondary Objectives : - To evaluate dose response relationship single IV dose HM10760A pharmacodynamic parameter - To assess immunogenicity single IV dose HM10760A .</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Healthy Caucasian Japanese male and/or female volunteer Age 18 55 year Hemoglobin &gt; 12 g/dL &lt; 16 g/dL male subject , &gt; 10 g/dL &lt; 14 g/dL female Caucasian subject Prior exposure EPO , darbepoetin , EPO support proteins hypersensitivity EPO , darbepoetin , E.coli derive protein Hemoglobinopathy SBP &gt; 140 mmHg &lt; 90 mmHg DBP &gt; 95 mmHg Chronic , uncontrolled , symptomatic inflammatory disease Malignancy ( except nonmelanoma skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>Long-acting</keyword>
	<keyword>EPO</keyword>
</DOC>